Rubicon as a Molecular Gatekeeper: Active Suppression of Autophagy in Aging Protects Cellular Integrity by Limiting Autophagic Flux to Prevent Over‑digestion of Essential Components

Evidence shows that Rubicon accumulates with age and directly blocks autophagosome‑lysosome fusion [1]. Rather than a simple failure of the cleanup system, we hypothesize that aged cells deliberately upregulate Rubicon to throttle autophagy and thereby preserve a limited pool of functional organelles and proteins. In this view, Rubicon acts as a molecular gatekeeper that restricts the bulk autophagic engine while permitting selective, low‑level turnover of severely damaged cargo. This restraint prevents the cell from exhausting essential components during a period when lysosomal capacity is compromised and the risk of inadvertent self‑digestion is high.

Mechanistic rationale

• Rubicon binds the Beclin‑1 complex, slowing autophagosome maturation [1]. In aged cells, persistent mTORC1 activity inhibits the autophagy‑dependent degradation of Rubicon [2], creating a feedback loop that sustains the blockade.
• Simultaneously, age‑related oxidative stress modifies ATG3/ATG7, stalling LC3 lipidation [4]. The combined effect reduces the overall autophagic flux to a basal level that can still clear the most toxic aggregates without threatening the structural integrity of mitochondria, ER, or lysosomal membranes.
• By limiting flux, Rubicon may also sequester damaged mitochondria within autophagosome‑like compartments that are not yet fused to lysosomes, isolating reactive oxygen species and preventing widespread oxidative damage. This sequestration buys time for repair pathways (e.g., mitochondrial fission/fusion, chaperone‑mediated refolding) to act before the organelle is finally degraded.
• The resulting low‑grade autophagic activity maintains intracellular amino acid pools that reinforce lysosomal mTORC1 signaling [3], further stabilizing the suppressed state.
• In senescent cells, the SASP reinforces this circuit by spreading mTORC1‑activating signals to neighbors, amplifying the suppression [6].

Testable predictions

1. Co‑immunoprecipitation – In lysates from aged mouse liver or human fibroblasts, Rubicon will pull down markers of damaged mitochondria (e.g., TOMM20, phospho‑Ubiquitin) more efficiently than in young controls.
2. Flux versus viability – Acute siRNA‑mediated Rubicon knockdown in aged cells will increase LC3‑II turnover and mitochondrial clearance (measured by mt‑Keima), but will also cause a transient drop in ATP and rise in caspase‑3 activity unless combined with low‑dose rapamycin (which promotes mTORC1‑dependent Rubicon degradation [2]).
3. Intermittent mTORC1 inhibition – Pulsed rapamycin treatment (2 h every 24 h) in aged mice will reduce Rubicon protein levels [2], restore autophagic flux [5], and improve tissue function without increasing apoptosis markers.
4. Young plasma effect – Administration of young plasma to aged primary hepatocytes will lower Rubicon expression and SASP cytokines [6], an effect blocked by neutralizing IL‑6 or TGF‑β antibodies.

Falsifiability – If Rubicon knockdown in aged cells does not increase sequestration of damaged mitochondria, or if Rubicon levels remain high despite mTORC1 inhibition and young plasma exposure, the gatekeeper model would be refuted. Conversely, confirmation of these predictions would support the idea that autophagy suppression in aging is an active, protective strategy rather than mere decay.